Biologic and synthetic skin substitutes

Series
Dermatology
Status
Published
Date
Number of report
084

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of biologic and synthetic skin substitutes in European countries.

The following clinical indications will be considered:

  • burns;
  • chronic wounds (hypertrophic scar).

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of biologic and synthetic skin substitutes include:

  • Allergan (AlloDerm)
  • Anika Therapeutics (HYALOMATRIX)
  • Avita Medical (ReCell)
  • Eurosurgical (Pelnac)
  • Hans Biomed (SureDerm)
  • Integra LifeSciences (Dermal Regeneration Template)
  • MedSkin Solutions (MatriDerm)
  • MiMedx Group (AmnioFix, EpiFix, EpiBurn, AmnioCord, AmnioFill)
  • Modex Therapeutiques (EpiDex)
  • Olympus Terumo Biomaterials (Terudermis)
  • Organogenesis (Dermagraft, NuShield, Affinity, Apligraf)
  • Ortec International (OrCel)
  • Osiris Therapeutics (Grafix, Grafix PL prime)
  • Promethean LifeSciences (GammaGraft)
  • Regenicin (PermaDerm)
  • Smith & Nephew (Biobrane, Oasis, Oasis Ultra)
  • Stryker (DermACELL)
  • Vericel Corporation (Epicel)
  • Wright Medical (GRAFTJACKET)

Table of content is not available at the moment. Report is still ongoing.

06

Jul 2021

In June 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (laser lithotripsy for difficult-to-treat bile duct stones and percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve), one new Medical Technologies Guidance (Plus Sutures for preventing surgical site infection), and four new Medtech Innovation Briefings (RapidAI for analyzing CT/MRI brain scans, WoundExpress, Magtrace and Sentimag, and SYNE-COV). Also, four clinical guidelines were updated, and two new published.

Read more

18

Jun 2021

In May 2021, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (ex-situ machine perfusion for extracorporeal preservation of lungs for transplant, transvaginal laser therapy for stress urinary incontinence and for urogenital atrophy, electrohydraulic lithotripsy for difficult-to-treat bile duct stones, and permanent His-bundle pacemaker for heart failure), one new Medical Technologies Guidance (UroLift for benign prostatic hyperplasia), and two new Medtech Innovation Briefings (Axonics sacral neuromodulation system for faecal incontinence and KODEX-EPD for cardiac imaging during ablation of arrhythmias). Also, three clinical guidelines and two Medical Technologies Guidance were updated.

Read more

05

Mar 2021

In February 2021, the National Institute for Health and Care Excellence (NICE) published one new medical technologies guidance (Leukomed Sorbact for preventing surgical site infection) and seven new Medtech innovation briefings (PROPEL sinus implants, URO17 for detecting bladder cancer, Faecal microbiota transplant, DOAC Dipstick for detecting oral anticoagulants, CytoSorb for reducing the risk of bleeding during cardiac surgery, and others).

Read more

01

Apr 2020

The report presents a summary of the reimbursement situation for the use of negative pressure wound therapy (NPWT) (procedure and medical aid) in Europe. The following clinical indications are considered: diabetic foot ulcer; venous leg ulcer; pressure ulcer. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more

20

Sep 2019

The report presents a summary of the reimbursement situation for use of biologic and synthetic skin substitutes in Europe. The following clinical indications are considered: burns; chronic wounds (hypertrophic scar). The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more
(we accept only company emails)